NASDAQ:RYTM

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

$17.66

+0.22 (+1.26%)

(As of 03/30/2023 04:00 PM ET)

Add

Compare

Today's Range: $16.90
▼
$18.04
50-Day Range: $16.88
▼
$31.14
52-Week Range: $3.04
▼
$34.99

Volume: 1.19 million shs
Average Volume: 639,509 shs
Market Capitalization: $1.00 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.00

Institutional Ownership

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 103.9% Upside
$36.00 Price Target
Short Interest: Bearish
15.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.80
Upright™ Environmental Score
News Sentiment: 0.48
Based on 7 Articles This Week
Insider Trading: Selling Shares
$172,045 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.95) to ($2.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

216th out of 999 stocks

Pharmaceutical Preparations Industry

88th out of 489 stocks

4.3

Analyst's Opinion

Consensus Rating
Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.00, Rhythm Pharmaceuticals has a forecasted upside of 103.9% from its current price of $17.66.
Amount of Analyst Coverage
Rhythm Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
15.03% of the float of Rhythm Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Rhythm Pharmaceuticals has recently decreased by 9.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Rhythm Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rhythm Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Rhythm Pharmaceuticals is -1.80.

2.5

News and Social Media Coverage

News Sentiment
Rhythm Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Rhythm Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for RYTM on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $172,045.00 in company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Rhythm Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.95) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rhythm Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rhythm Pharmaceuticals is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rhythm Pharmaceuticals has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

March 30, 2023 | marketwatch.com

Mobile Music Rhythm Games Market 2023 Huge Demand, Growth Opportunities and Expansion by 2029

March 29, 2023 | marketwatch.com

Rhythm Energy Named Retail Energy Provider of the Year

March 30, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 28, 2023 | marketwatch.com

Mobile Music Rhythm Games Market Demand and Competitive Analysis by Key Players to 2030| Tencent, C4Cat, T3 Entertainment

March 28, 2023 | marketwatch.com

Mobile Music Rhythm Games Market [ R and D ] till 2030

March 27, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

March 21, 2023 | msn.com

Geek Review: Rhythm Sprout

March 6, 2023 | nasdaq.com

Rhythm Pharmaceuticals Becomes Oversold (RYTM)

March 30, 2023 | The Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 3, 2023 | marketwatch.com

Circadian Rhythm Sleep Disorders Market Size, Share & Trends Analysis Forecast Report by 2028

March 2, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2022 Earnings Call Transcript

March 2, 2023 | msn.com

Bhopal: Students, teachers dance, audience clap, tap at ‘Rhythm 2k23’

March 2, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Full Year 2022 Earnings: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

March 1, 2023 | marketwatch.com

Global Cardiac Rhythm Management (CRM) Devices Market by Segment, Price Trend 2023-2028

March 1, 2023 | msn.com

Rhythm Pharmaceuticals beats Q4 top and bottom line estimates; initiates FY23 outlook

March 1, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 28, 2023 | marketwatch.com

Circadian Rhythm Sleep Treatment Market Size with Competitive Landscape, New Projects and Investment Analysis till 2028

February 28, 2023 | marketwatch.com

Circadian Rhythm Sleep Disorder Market Size 2023 With Strategic Choice-Making Process, Identification of Main Corporations

February 27, 2023 | marketwatch.com

Circadian Rhythm Sleep Disorder Market 2023 : Business Scenario, Corporate Profiles, Size and Dynamic Innovation by 2028

February 27, 2023 | finanznachrichten.de

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

February 27, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

February 23, 2023 | marketwatch.com

Global Cardiac Rhythm Management Systems Market Analysis By Type Technology End-Use By Region By Country and Forecast 2023 to 2030 By VMReports

February 22, 2023 | marketwatch.com

Cardiac Rhythm Management Device Market is Expected to Record Huge Growth, Emerging Trend, and Analysis by Top Prominent Players from 2023-2028

February 21, 2023 | marketwatch.com

Cardiac Monitoring and Cardiac Rhythm Management Device Market Size, Outlook, Share, Prominent Players, Growth, and Forecast 2028

February 21, 2023 | finance.yahoo.com

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

February 21, 2023 | marketwatch.com

Electronic Rhythm Machines Market Size with Competitive Landscape, New Projects and Investment Analysis till 2028

February 17, 2023 | marketwatch.com

Cardiac Rhythm Management Market In 2023 By In-depth Analysis of Revenue Forecast and Competitive Landscape 2028

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings: 3/01/2023
Today: 3/30/2023
Next Earnings (Estimated): 5/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RYTM
CUSIP: N/A
CIK: 1649904
Web: www.rhythmtx.com
Phone: (857) 264-4280
Fax: 857-264-4299
Employees: 140
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $36.00
High Stock Price Forecast: $56.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +106.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-181,120,000.00
Net Margins: -766.22%
Pretax Margin: -766.22%
Return on Equity: -74.17%
Return on Assets: -54.28%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.90
Quick Ratio: 8.83

Sales & Book Value

Annual Sales: $23.64 million
Price / Sales: 41.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.69 per share
Price / Book: 3.72

Miscellaneous

Outstanding Shares: 56,750,000
Free Float: 54,592,000
Market Cap: $989.72 million
Optionable: Optionable
Beta: 1.82

Key Executives

David P. Meeker
Chairman, President & Chief Executive Officer

Hunter C. Smith
Chief Financial Officer & Treasurer

Brieana Buckley
Vice President-Medical Affairs

Joseph Shulman
Chief Technical Officer

Yann Mazabraud
Executive Vice President & Head-International

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.
What is Rhythm Pharmaceuticals' stock price forecast for 2023?: 6 analysts have issued 1 year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $56.00. On average, they expect the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.
How have RYTM shares performed in 2023?: Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 40.1% and is now trading at $17.44.
View the best growth stocks for 2023 here.
When is Rhythm Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our RYTM earnings forecast.
How were Rhythm Pharmaceuticals' earnings last quarter?: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Wednesday, March, 1st. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.07. The company earned $8.80 million during the quarter, compared to analyst estimates of $7.16 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 74.17% and a negative net margin of 766.22%. The business's quarterly revenue was up 388.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) earnings per share.
What ETFs hold Rhythm Pharmaceuticals' stock?: ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA SmallCap Momentum ETF (DWAS), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED) and IQ Healthy Hearts ETF (HART).
What other stocks do shareholders of Rhythm Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?: (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
What is Rhythm Pharmaceuticals' stock symbol?: Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
Who are Rhythm Pharmaceuticals' major shareholders?: Rhythm Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.79%), NEA Management Company LLC (8.71%), Alkeon Capital Management LLC (3.97%), Opaleye Management Inc. (1.30%), Assenagon Asset Management S.A. (0.82%) and Geode Capital Management LLC (0.81%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends.
How do I buy shares of Rhythm Pharmaceuticals?: Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rhythm Pharmaceuticals' stock price today?: One share of RYTM stock can currently be purchased for approximately $17.44.
How much money does Rhythm Pharmaceuticals make?: Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $989.72 million and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.
How many employees does Rhythm Pharmaceuticals have?: The company employs 140 workers across the globe.
How can I contact Rhythm Pharmaceuticals?: Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

Rhythm Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

RYTM Stock News Headlines

RYTM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RYTM Stock - Frequently Asked Questions

Overall MarketRank^™